The effect of β-blocker treatment on renin (A) and aldosterone-to-renin ratio (B). by Ningning Wang (560944)

Subjects:

Complication subgroup analysis of the RAAS system in T2DM patients. by Ningning Wang (560944)

Subjects:

Flow diagram of patient selection and subgroup classification. by Ningning Wang (560944)

Subjects:

The values of angiotensin II by Ningning Wang (560944)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different hypertension subgroups. by Ningning Wang (560944)

Subjects:

General characterization of T2DM patients and healthy controls. by Ningning Wang (560944)

Subjects:

Antihypertensive treatment of 151 T2DM patients with hypertension at different subgroups. by Ningning Wang (560944)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different normotension subgroups. by Ningning Wang (560944)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes in hypertensive (A) and normotensive (B) patients. by Ningning Wang (560944)

Subjects:

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Multiple linear regression analysis results. by Muxi Chen (9294270)

Subjects:

Estimation of the coefficients of a generalised linear model of posttraumatic stress symptomatology. by Beatriz Arregui-Gallego (21553735)

Subjects:

Linear trends of weekly prescription rates of NVBP varieties. by Chenxuan Zhu (22622476)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”

Significant condition. by Junxia Zhou (14381598)

“…BET and SEM analyses demonstrated that the specific surface area and porosity (most probable pore size) gradually decreased over time. At various ages, mesopores (cumulative pore diameter, median pore diameter) initially increased and then decreased. …”